Table 1 Study population characteristics
From: Evaluation and comparison of different breast cancer prognosis scores based on gene expression data
Characteristic | Patients (n = 1980) |
|---|---|
Median age at diagnosis, years (range) | 61.8 (21.9–96.3) |
Inferred menopausal state (%) | |
Pre-menopausal | 424 (21) |
Menopausal | 1556 (79) |
Oestrogen receptor status (%) | |
Positive | 1506 (76) |
Negative | 474 (24) |
Progesterone receptor status (%) | |
Positive | 1040 (53) |
Negative | 940 (47) |
HER2 receptor status (%) | |
Positive | 247 (12) |
Negative | 1733 (88) |
Stage (%) | |
In situ | 12 (1) |
I | 501 (25) |
II | 825 (42) |
III | 118 (6) |
IV | 10 (1) |
Not specified | 514 (26) |
Grade (%) | |
1 | 169 (9) |
2 | 772 (39) |
3 | 955 (48) |
Not specified | 84 (4) |
Median tumour size, mm (range) | 23 (1–403) |
Lymph node involvement (%) | |
Negative | 1043 (53) |
Positive | 937 (47) |
Surgery (%) | |
Breast-conserving | 785 (40) |
Mastectomy | 1170 (59) |
Not specified | 25 (1) |
Chemotherapy (%) | |
None | 1568 (79) |
Second generation | 395 (20) |
Third generation | 17 (1) |
Radiotherapy (%) | |
Not received | 810 (41) |
Received | 1170 (59) |
Hormone therapy (%) | |
Not received | 764 (39) |
Received | 1216 (61) |